Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 30, 2019 - Issue 1
Submit an article Journal homepage
873
Views
16
CrossRef citations to date
0
Altmetric
Psoriasis and atopic dermatitis

Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial

April ArmstrongKeck School of Medicine, University of Southern California, Los Angeles, CA, USA; View further author information
,
Luis PuigHospital de la Santa Creu i Sant Pau and Universitat Autònoma de Barcelona, Barcelona, Spain; View further author information
,
Richard LangleyDalhousie University, Halifax, Nova Scotia; View further author information
,
Tsen Fang TsaiNational Taiwan University Hospital, Taipei, Taiwan; View further author information
,
Michael SongJanssen Research and Development, LLC, Spring House, PA, USAView further author information
,
Yasmine WasfiJanssen Research and Development, LLC, Spring House, PA, USAView further author information
,
Jingzhi JiangJanssen Research and Development, LLC, Spring House, PA, USAView further author information
,
Shu LiJanssen Research and Development, LLC, Spring House, PA, USAView further author information
&
Chenglong HanJanssen Research and Development, LLC, Spring House, PA, USACorrespondence[email protected]
View further author information
 show all
Pages 27-34 | Received 05 Jul 2017, Accepted 01 Aug 2017, Published online: 24 Sep 2018

References

  • Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
  • Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–516.
  • Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–139.
  • Marquis P, Arnould B, Acquadro C, et al. Patient-reported outcomes and health-related quality of life in effectiveness studies: pros and cons. Drug Dev Res. 2006;67:193–201.
  • Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. 2009; http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Last accessed on August 20, 2018.
  • Feldman SR, Mathias SD, Schenkel B, et al. Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary. J Dermatol & Dermatol Surg. 2016;20:19–26.
  • Mathias SD, Feldman SR, Crosby RD, et al. Measurement properties of a patient reported outcome measure assessing psoriasis severity: the Psoriasis Symptoms and Signs Diary. J Dermatol Treat. 2016;27:322–327.
  • Langley RG, Tsai T-F, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: Results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178:114–123.
  • Finlay AY, Khan GK . Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–216.
  • Fredriksson T, Pettersson U . Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
  • Chalmers R. Psoriasis Area & Severity Index. http://www.papaa.org/articles/psoriasis-area-severity-index. 2008; Last accessed on August 20, 2018.
  • Schmitt J, Wozel G. The Psoriasis Area and Severity Index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology. 2005;210:194–199.
  • Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatol Treat. 2004;15:27–29.
  • Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.